PBYI vs. ADMA, CTMX, TRDA, SPRY, UPB, CRON, NBTX, VALN, PGEN, and SYRE
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), ARS Pharmaceuticals (SPRY), Upstream Bio (UPB), Cronos Group (CRON), Nanobiotix (NBTX), Valneva (VALN), Precigen (PGEN), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.
Puma Biotechnology vs. Its Competitors
Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Puma Biotechnology has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
Puma Biotechnology currently has a consensus price target of $7.00, indicating a potential upside of 33.69%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 85.78%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Puma Biotechnology.
In the previous week, Puma Biotechnology had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 5 mentions for Puma Biotechnology and 4 mentions for ADMA Biologics. Puma Biotechnology's average media sentiment score of 1.20 beat ADMA Biologics' score of 0.70 indicating that Puma Biotechnology is being referred to more favorably in the media.
ADMA Biologics has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 23.3% of Puma Biotechnology shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ADMA Biologics has a net margin of 44.06% compared to Puma Biotechnology's net margin of 20.38%. Puma Biotechnology's return on equity of 53.15% beat ADMA Biologics' return on equity.
Summary
ADMA Biologics beats Puma Biotechnology on 11 of the 17 factors compared between the two stocks.
Get Puma Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Puma Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:PBYI) was last updated on 10/14/2025 by MarketBeat.com Staff